Y Intercept Hong Kong Ltd Purchases Shares of 32,067 SI-BONE, Inc. (NASDAQ:SIBN)

Y Intercept Hong Kong Ltd acquired a new stake in SI-BONE, Inc. (NASDAQ:SIBN) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 32,067 shares of the company’s stock, valued at approximately $448,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of SIBN. FMR LLC raised its holdings in shares of SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after acquiring an additional 1,198 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in SI-BONE during the 2nd quarter valued at $61,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after purchasing an additional 2,108 shares in the last quarter. Arizona State Retirement System lifted its position in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after purchasing an additional 903 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of SI-BONE during the 3rd quarter valued at about $144,000. 98.11% of the stock is owned by institutional investors.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,937 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.60, for a total transaction of $49,606.20. Following the completion of the sale, the insider now directly owns 228,554 shares in the company, valued at approximately $2,879,780.40. This trade represents a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Laura Francis sold 10,048 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the completion of the transaction, the chief executive officer now owns 482,875 shares in the company, valued at approximately $6,074,567.50. This represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,679 shares of company stock worth $276,439. 3.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a research note on Wednesday, November 20th. Truist Financial increased their target price on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.00.

SI-BONE Stock Performance

Shares of SIBN opened at $13.77 on Tuesday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a market cap of $577.51 million, a P/E ratio of -14.97 and a beta of 1.20. The business’s 50 day moving average price is $13.40 and its 200-day moving average price is $14.10. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $21.70.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.